"The acquisition of DNA Genotek ... (provides) OraSure with a complementary portfolio of products that enable easy and reliable collection, stabilization, transportation and storage of high quality nucleic acid (DNA and RNA) samples," the Pennsylvania-based firm said in a statement.
In a previous conference call with analysts, DNA Genotek chief executive Ian Curry said the only change is he will report to OraSure president and CEO Douglas Michels, rather than DNA Genotek's board.
The 70-person firm expects to keep growing in the wake of the acquisition. It was one of OBJ's Fastest-Growing Companies in 2010 with three-year revenue growth of 153 per cent.
Founded in 1998, DNA Genotek's technology lets DNA samples be analyzed from saliva rather than blood, which the company says is a less invasive way of doing tests.
Recently it has expanded from medical work into livestock and the space sector.
OraSure develops, manufactures and markets oral fluid specimen devices, focusing on infectious diseases such as HIV.
